Advertisement
Advertisement
NEO
NeoGenomics, Inc.
7.75
USDSponsored
-0.01
-0.19%
Mar 26, 15:58 UTC -4
Closed
After-Market
7.76
+0.01
+0.12%
NEO Earnings Reports
Positive Surprise Ratio
NEO beat 36 of 41 last estimates.
88%
Next Report
Date of Next Report
Apr 27, 2026
Estimate for Q1 26 (Revenue/ EPS)
$186.38M
/$0.00
Implied change from Q4 25 (Revenue/ EPS)
-1.99%
/-100.00%
Implied change from Q1 25 (Revenue/ EPS)
+10.92%
/--
NeoGenomics, Inc. earnings per share and revenue
On Feb 17, 2026, NEO reported earnings of 0.06 USD per share (EPS) for Q4 25, beating the estimate of 0.03 USD, resulting in a 53.45% surprise. Revenue reached 190.17 million, compared to an expected 189.93 million, with a 0.12% difference. The market reacted with a +3.52% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 14 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 186.38 million USD, implying an decrease of -100.00% EPS, and decrease of -1.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were NeoGenomics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, NeoGenomics, Inc. reported EPS of $0.06, beating estimates by 53.45%, and revenue of $190.17M, 0.12% above expectations.
How did the market react to NeoGenomics, Inc.'s Q4 2025 earnings?
The stock price moved up 3.52%, changed from $12.49 before the earnings release to $12.93 the day after.
When is NeoGenomics, Inc. expected to report next?
The next earning report is scheduled for Apr 27, 2026.
What are the forecasts for NeoGenomics, Inc.'s next earnings report?
Based on 14
analysts, NeoGenomics, Inc. is expected to report EPS of -- and revenue of $186.38M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement